Subscribe
istock-866149824natee-meepian
Natee Meepian / iStockphoto.com
13 September 2018Americas

Bausch Health settles generic dispute with Actavis

Canada-based Bausch Health has agreed to settle all IP litigation with Actavis over antibiotic drug Xifaxan (rifaximin).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Eli Lilly refused injunction against Teva, Actavis and Mylan
17 November 2017   The English High Court has refused to grant Eli Lilly an injunction which would have stopped Teva, Actavis and Mylan marketing a generic version of its drug Cialis (tadalafil).
Americas
Bausch Health resolves IP litigation with Teva
2 August 2019   Canadian pharmaceutical company Bausch Health and generics maker Teva have resolved their dispute over Apriso (mesalazine), a drug used to treat ulcerative colitis and Crohn's disease.
Americas
Bausch Health resolves patent litigation with Glenmark
23 December 2019   Canadian pharmaceutical company Bausch Health and India-based Glenmark Pharmaceuticals have resolved their outstanding IP litigation over Bryhali lotion.


Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024

Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

More on this story

Big Pharma
Eli Lilly refused injunction against Teva, Actavis and Mylan
17 November 2017   The English High Court has refused to grant Eli Lilly an injunction which would have stopped Teva, Actavis and Mylan marketing a generic version of its drug Cialis (tadalafil).
Americas
Bausch Health resolves IP litigation with Teva
2 August 2019   Canadian pharmaceutical company Bausch Health and generics maker Teva have resolved their dispute over Apriso (mesalazine), a drug used to treat ulcerative colitis and Crohn's disease.
Americas
Bausch Health resolves patent litigation with Glenmark
23 December 2019   Canadian pharmaceutical company Bausch Health and India-based Glenmark Pharmaceuticals have resolved their outstanding IP litigation over Bryhali lotion.

More on this story

Big Pharma
Eli Lilly refused injunction against Teva, Actavis and Mylan
17 November 2017   The English High Court has refused to grant Eli Lilly an injunction which would have stopped Teva, Actavis and Mylan marketing a generic version of its drug Cialis (tadalafil).
Americas
Bausch Health resolves IP litigation with Teva
2 August 2019   Canadian pharmaceutical company Bausch Health and generics maker Teva have resolved their dispute over Apriso (mesalazine), a drug used to treat ulcerative colitis and Crohn's disease.
Americas
Bausch Health resolves patent litigation with Glenmark
23 December 2019   Canadian pharmaceutical company Bausch Health and India-based Glenmark Pharmaceuticals have resolved their outstanding IP litigation over Bryhali lotion.

More features

Bayer gains exclusive licence for heart drug in Japan
EPO delivers key Novo Nordisk, GSK and Inhibrx rulings
McGuireWoods expands team with ex-Novo Nordisk GC
Paul, Weiss swoops for senior duo from Weil, Gotshal
UPC bans Meril Life Sciences from selling infringing heart valve
SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic
Kathi Vidal to rejoin previous firm as partner following USPTO departure
GSK triumphs in EPO appeal, revoking Pfizer patent